ArticleNature medicine2024
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.
Abstract read
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective.Frontiers in immunology · 2026Pooled it
- Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025).Frontiers in immunology · 2026Pooled it
- Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.Nature medicine · 2025Trial
- Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference.Journal of the American Society of Nephrology : JASN · 2026Article
- Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis.Kidney international reports · 2026Article
- Review
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Uncovering ectopic GC-like niches for tumor reactive lymphocyte priming in lung adenocarcinoma using Stereo-XCR-seq.Nature communications · 2026Article
- Mapping mesenchymal diversity in the human small intestine and organoids.Nature cell biology · 2026Article
- GZMK-expressing tissue-resident memory CD8+ T cells participate in human intestinal acute graft-versus-host disease.JCI insight · 2026Article
- Single-cell spatial transcriptomics of formalin-fixed, paraffin-embedded biopsies reveals colitis-associated cell networks.The Journal of clinical investigation · 2026Article
- The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.Immunological reviews · 2026Review
- Microbiota and immune-related adverse events in cancer immunotherapy.Nature reviews. Cancer · 2026Review
- Comprehensive characterization of the inflammatory ecosystems in immunotherapy-induced adverse events versus chronic inflammatory diseases.Journal for immunotherapy of cancer · 2026Article
- Spatial Immunology in Translation: Linking Immune Organisation to Therapeutic Outcome.Medical sciences (Basel, Switzerland) · 2026Review
- Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.bioRxiv : the preprint server for biology · 2026Article
- Toward Precision Health in Autoimmunity and Immune-Related Adverse Events: The Autoantibody Reactome, Spatial Omics, and Multimodal Data Integration.Biomedicines · 2026Article
- Tissue-resident memory T cells in organ transplantation: implications for immune homeostasis and graft outcomes.Inflammation and regeneration · 2026Review
- Deciphering immune and cellular reprogramming during the progression from inflammatory bowel disease to colorectal cancer using multi-omics single-cell and spatial transcriptomics.Journal of translational medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Molly Fisher Thomas *Department of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA. thomamol@ohsu.edu.ORCID 0000-0002-1393-6559
Kamil Slowikowski *Department of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA. kslowikowski@mgh.harvard.edu.ORCID 0000-0002-2843-6370
Kasidet ManakongtreecheepDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Pritha SenDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Nandini SamantaDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Jessica TantivitDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-2179-0377
Mazen NasrallahDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Leyre ZubiriKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Neal P SmithDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-1394-3158
Alice TirardDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Swetha RameshDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-7833-165X
Benjamin Y ArnoldDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Linda T NiemanKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Jonathan H ChenKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Thomas EisenhaureBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Karin PelkaKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-2856-8602
Yuhui SongKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-5087-4684
Katherine H XuKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Vjola JorgjiKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Christopher J PintoClinical Research Center, Massachusetts General Hospital, Boston, MA, USA.
Tatyana SharovaDepartment of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Rachel GlasserDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
PuiYee ChanHarvard Medical School, Boston, MA, USA.
Ryan J SullivanHarvard Medical School, Boston, MA, USA.ORCID 0000-0001-5344-6645
Hamed KhaliliBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7956-6941
Dejan JuricBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0003-2983-7704
Genevieve M BolandKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-7522-6173
Michael DouganHarvard Medical School, Boston, MA, USA.
Nir HacohenKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-2349-2656
Bo LiDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Kerry L ReynoldsHarvard Medical School, Boston, MA, USA.
Alexandra-Chloé VillaniDepartment of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA. avillani@mgh.harvard.edu.ORCID 0000-0001-7461-0408
Funding
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Curtis Huttenhower · 1991 to 2026
$35.3MRESEARCH TRAINING IN DIGESTIVE DISEASES AND NUTRITIONT32DK007191 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1986 to 2026
$14.6MResearch Training in Rheumatology at Massachusetts General HospitalT32AR007258 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1986 to 2026
$6.9MMolecular Pathways Regulating Tissue-resident Memory T cells in the GutR01AI169188 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Michael Lawrence Dougan · 2022 to 2026
$3.0MMedications, the gut microbiota, and risk of microscopic colitisR01AG068390 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI KHALILI, HAMED · 2020 to 2024
$2.5MDeciphering the Achilles Heel of Cancer ImmunotherapyDP2CA247831 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI VILLANI, ALEXANDRA-CHLOE · 2019 to 2019
$2.5MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MHigh-dimensional single-cell mapping to define immune signatures of cytomegalovirus-associated rejection in cardiac transplantationK08HL157725 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI SEN, PRITHA · 2021 to 2025
$929kUnraveling the Role of PD-1 in CD8+ Tissue-Resident Memory T Cell Homeostasis and Epithelial Damage in Human ColitisK08DK127246 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI Molly Thomas · 2022 to 2026
$864kMalignant Cell Engagement in Immune Circuits of Human Microsatellite-stable and Microsatellite-instable Colorectal CancerR00CA259511 · NCI · J. DAVID GLADSTONE INSTITUTES · PI PELKA, KARIN · 2021 to 2023
$747kDelineating the mechanisms by which tumor immunity multicellular networks shape T cell stateK08CA273547 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHEN, JONATHAN HOWARD · 2023 to 2025
$680kNCI NIH HHS DP2 CA247831NCI NIH HHS K08 CA273547NCI NIH HHS R00 CA259511NCI NIH HHS T32 CA207021NHLBI NIH HHS K08 HL157725NIAID NIH HHS R01 AI169188NIAMS NIH HHS T32 AR007258NIA NIH HHS R01 AG068390NIDDK NIH HHS K08 DK127246NIDDK NIH HHS P30 DK043351NIDDK NIH HHS T32 DK007191U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) DP2CA247831U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) K08DK127246U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) T32DK007191
Abstract
Immune checkpoint inhibitor (ICI) therapy has revolutionized oncology, but treatments are limited by immune-related adverse events, including checkpoint inhibitor colitis (irColitis). Little is understood about the pathogenic mechanisms driving irColitis, which does not readily occur in model organisms, such as mice. To define molecular drivers of irColitis, we used single-cell multi-omics to profile approximately 300,000 cells from the colon mucosa and blood of 13 patients with cancer who developed irColitis (nine on anti-PD-1 or anti-CTLA-4 monotherapy and four on dual ICI therapy; most patients had skin or lung cancer), eight controls on ICI therapy and eight healthy controls. Patients with irColitis showed expanded mucosal Tregs, ITGAE
Indexed as
ColitisImmune Checkpoint InhibitorsIntestinal MucosaSingle-Cell AnalysisAgedCD8-Positive T-LymphocytesColonCTLA-4 AntigenEpithelial CellsFemaleGene Expression ProfilingHumansMaleMiddle AgedProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryCTLA-4 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.